Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyxeos in Newly Diagnosed Low- or Intermediate-risk AML
NCT05599360Phase 2Active, not recruiting
- Sponsor
- Shaare Zedek Medical Center
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine in acute myeloid leukemia (AML), sponsored by Shaare Zedek Medical Center. Started Aug 2022; status: active, not recruiting.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05599360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599360.